Views

CrossRef citations to date

Altmetric

Clinical Trial Report

Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study

Roland Buhl1 Pulmonary Department, Mainz University Hospital, Mainz, [email protected]Correspondence[email protected]

Carl-Peter Criée2 Department of Sleep and Respiratory Medicine, Evangelical Hospital Goettingen-Weende, Bovenden

Peter Kardos3 Group Practice and Centre for Allergy, Respiratory and Sleep Medicine, Red Cross Maingau Hospital, Frankfurt am Main

Claus F Vogelmeier4 Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Member of the German Center for Lung Research (DZL), Marburg, Germany

Konstantinos Kostikas5 WorldWide Medical Affairs Respiratory, Novartis Pharma AG, Basel, Switzerland

Nadine S Lossi6 Clinical Research, Respiratory, Novartis Pharma GmbH, Nürnberg

Heinrich Worth7 Facharztforum Fürth, Fürth, Germany

show all

Figures & data

Figure 1 Patient disposition, including numbers of patients included in the initial matched-pairs analysis and those included in the subsequent analyses by prior COPD maintenance therapy.

Abbreviations: ICS, inhaled corticosteroid; LA BA, long-acting β₂-agonist; LA MA, long-acting muscarinic antagonist.

Figure 2 Prior therapy, according to post-baseline treatment group in the matched-pair analysis (n=2,092).

Note: ^aIncludes patients receiving only short-acting bronchodilators and those receiving regimens containing theophylline and/or phosphodiesterase-4 inhibitors.
Abbreviations: ICS, inhaled corticosteroid; LA BA, long-acting β₂-agonist; LA MA, long-acting muscarinic antagonist.

Table 1 Baseline demographics and disease characteristics of patients subgrouped according to prior therapy

Download CSV Display Table

Figure 3 Percentage of patients reporting exacerbations over the 1-year follow-up in patients subgrouped according to prior therapy.

Abbreviations: LA BA, long-acting β₂-agonist; LA MA, long-acting muscarinic antagonist.

Figure 4 Annualized moderate and severe exacerbation rates in patients subgrouped according to prior therapy.

Abbreviations: LA BA, long-acting β₂-agonist; LA MA, long-acting muscarinic antagonist.

Table 2 CAT total score at month 12 – change from baseline in total score and responder analysis in patients subgrouped according to prior therapy

Download CSV Display Table

Table S1 Baseline demographics and disease characteristics of patients, overall and in the matched-pairs analysis

Download CSV Display Table

Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study

Table 1 Baseline demographics and disease characteristics of patients subgrouped according to prior therapy

Table 2 CAT total score at month 12 – change from baseline in total score and responder analysis in patients subgrouped according to prior therapy

Table S1 Baseline demographics and disease characteristics of patients, overall and in the matched-pairs analysis

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study

Figures & data

Table 1 Baseline demographics and disease characteristics of patients subgrouped according to prior therapy

Table 2 CAT total score at month 12 – change from baseline in total score and responder analysis in patients subgrouped according to prior therapy

Table S1 Baseline demographics and disease characteristics of patients, overall and in the matched-pairs analysis

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date